Clinical Trial Update: Study of WAL0921 in Patients With Glomerular Kidney Diseases [Phase 2]

View source ↗

Summary

Walden Biosciences reports a Phase 2 clinical trial of WAL0921 in multiple glomerular diseases, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Focal Segmental Glomerulosclerosis
• Iga Nephropathy
• Membranous Nephropathy
• Minimal Change Disease

Drugs mentioned

• WAL0921

Snippet

Sponsor: Walden Biosciences | Conditions: Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis | Phase 2 | Status: RECRUITING